Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) has received an average rating of “Buy” from the ten ratings firms that are currently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $26.25.
Several equities research analysts have recently weighed in on the stock. Evercore ISI decreased their price objective on shares of Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, August 12th. William Blair reissued an “outperform” rating on shares of Cabaletta Bio in a research note on Monday, November 18th. TD Cowen raised shares of Cabaletta Bio to a “strong-buy” rating in a research note on Friday, November 29th. Wells Fargo & Company cut their target price on shares of Cabaletta Bio from $20.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Cabaletta Bio in a research note on Friday, November 15th.
Get Our Latest Analysis on CABA
Institutional Inflows and Outflows
Cabaletta Bio Stock Down 7.4 %
CABA opened at $3.25 on Friday. Cabaletta Bio has a twelve month low of $1.76 and a twelve month high of $26.35. The company has a fifty day moving average of $3.84 and a 200-day moving average of $6.03. The stock has a market cap of $158.86 million, a PE ratio of -1.51 and a beta of 2.37.
Cabaletta Bio Company Profile
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
Further Reading
- Five stocks we like better than Cabaletta Bio
- Roth IRA Calculator: Calculate Your Potential Returns
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- What is Insider Trading? What You Can Learn from Insider Trading
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.